Status: Recruiting
QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment. This study aims to enhance the anti-tumor immune effect through the combination of QL1706+Lenvatinib+AG regimen, thereby improving the prognosis of patients with advanced metastatic pancreatic cancer.
Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Du JuanUpdated: Jan 2, 2026Locations: 1
Eligibility criteria
a. Age ≥18 years, ECOG performance status ≤2, and expected survival of ≥3 months... [+7]
a. Prior receipt of systemic anti-tumor treatment, such as chemotherapy, radioth... [+10]